Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03563157
Other study ID # QUILT-3.071
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 25, 2018
Est. completion date December 30, 2022

Study information

Verified date March 2022
Source ImmunityBio, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

QUILT 3.071 NANT Colorectal Cancer (CRC) Vaccine: Phase 1b/2 NANT CRC Vaccine vs Regorafenib in Subjects with CRC Who have Previously Treated with SOC.


Description:

NANT Colorectal Cancer (CRC) Vaccine: A phase 1b/2 Trial of the NANT CRC Vaccine vs Regorafenib in Subjects with Metastatic CRC Who Have Been Previously Treated with Standard-Of-Care Therapy


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 332
Est. completion date December 30, 2022
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3. Histologically-confirmed recurrent or metastatic CRC previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy; or subjects who are ineligible for these therapies. 4. ECOG performance status of 0 or 1. 5. Have at least 1 measurable lesion of = 1.0 cm. 6. Must have a recent FFPE tumor biopsy specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used. 7. Must be willing to provide blood samples prior to the start of treatment on this study for prospective tumor molecular profiling and exploratory analyses. 8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator. 9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol. 10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, IUDs, and abstinence. Phase 2 single-arm component only 11. Must have progressed on or after regorafenib treatment in the randomized phase 2 portion of the study OR progressed or experienced unacceptable toxicity on SoC and regorafenib prior to enrollment on the study. Exclusion Criteria: 1. MSI-high or MMR-deficient tumors eligible for, but not yet treated with, a PD-1 inhibitor. 2. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drugs used in this study or that would put the subject at high risk for treatment-related complications. 3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, or autoimmune disease associated with lymphoma). 4. History of organ transplant requiring immunosuppression. 5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis). 6. Inadequate organ function, evidenced by the following laboratory results: 1. ANC < 1,000 cells/mm^3. 2. Uncorrectable grade 3 anemia (hemoglobin < 8 g/dL) 3. Platelet count < 75,000 cells/mm^3. 4. Total bilirubin > ULN (unless the subject has documented Gilbert's syndrome). 5. AST (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases). 6. ALP > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases). 7. Serum creatinine > 2.0 mg/dL or 177 µmol/L. 8. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3. 7. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry. 8. Serious myocardial dysfunction defined by ECHO as absolute LVEF 10% below the institution's lower limit of predicted normal. 9. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy. 10. Positive results of screening test for HIV. 11. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed. 12. Known hypersensitivity to any component of the study medication(s). 13. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. 14. Concurrent or prior use of a strong CYP3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1. 15. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1. 16. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer. 17. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol. 18. Concurrent participation in any interventional clinical trial. 19. Pregnant and nursing women. Phase 2 randomized component only 20. Prior regorafenib treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Aldoxorubicin Hydrochloride
Aldoxorubicin Hydrochloride HCI
ALT-803
Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
ETBX-011
Ad5 [E1-, E2b-]-CEA
ETBX-021
Ad5 [E1-, E2b-]-[HER2]
ETBX-051
Ad5 [E1-, E2b-]-Brachyury
ETBX-061
Ad5 [E1-, E2b-]-mucin 1 [MUC1]
GI-4000
RAS yeast
GI-6207
CEA yeast
GI-6301
Brachyury yeast
haNK
haNK™, NK-92 [CD16.158V, ER IL-2]
Drug:
Avelumab
BAVENCIO® injection
Capecitabine
XELODA® tablets
Cetuximab
ERBITUX® injection
Cyclophosphamide
Cyclophosphamide Capsules
5-Fluorouracil
5-FU; Fluorouracil Injection
Leucovorin
Leucovorin Calcium
Nab-paclitaxel
ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
Oxaliplatin
ELOXATIN® injection
Regorafenib
STIVARGA® tablets
Procedure:
SBRT
Stereotactic body radiation therapy

Locations

Country Name City State
United States Chan Soon-Shiong Institute for Medicine El Segundo California

Sponsors (1)

Lead Sponsor Collaborator
ImmunityBio, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03 Phase 1b 2 years
Primary Progression Free Survival from baseline to progression, per RECIST 1.1 Phase 2 Randomized Component 2 years
Primary Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1 Phase 2 Single Arm Component 1 year
Secondary ORR for Phase 1b and Phase 2 Randomized Component Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete response per RECIST 1.1 and irRC 1 year
Secondary PFS for Phase 1b and Phase 2 Single Arm Component Progression Free Survival from baseline to progression per RECIST 1.1 and irRC 2 years
Secondary OS for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component Overall Survival from first treatment to date of death (any cause) 2 years
Secondary DOR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component Duration of Response from date of first response to date of disease progression or death (any cause), per RECIST 1.1 and irRC 2 years
Secondary DCR for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component Disease Control Rate: the number of patients with a CR, PR or SD lasting at least 2 months per RECIST 1.1 and irRC 1 year
Secondary QoL for Phase 1b, Phase 2 Randomized, and Phase 2 Single Arm Component Quality of Life as assessed by Patient Reported Outcomes using the FACT-C questionnaire 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2